[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-risk":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,53,91,124,151,196,224,253,295,322,352,374,402,426,453,486,512,537,558],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100644418","cardiovascular-risk-in-patients-with-ibd-100644418",false,"NCT07663201","Cardiovascular Risk in Patients With IBD","Dissecting the Complexity of Inflammatory Bowel Disease (IBD) A Prospective Study With Focus on Cardiovascular Risk","DICOM-IBD","Inclusion Criteria:\n\nEstablished diagnosis of ulcerative colitis and Crohn's disease\n\nExclusion Criteria:\n\nAge \\> 18 years Not compliant with study protocol",true,"ALL","18 Years",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","In this study our Research Hospital San Donato Policlinic ask your partipation with the aim to evaluate the risk of cardiovascular complication (i.e. stroke, myocardial infarction) in patients with inflammatory bowel disease. Multiple parameters (therapy, disease activity, life style) and investigations (DNA, stool, lab tests) will be evaluate with the support of artificial intelligence methodologies to better define the cardiovascular risk.",[26,27,28],"Ulcerative Colitis (UC)","Crohn's Diseases","Cardiovascular Risk",[30,31,32,33,34,35,36,37,38,39,40],"Ulcerative colitis","Crohn's disease","Inflammatory bowel disease","Cardiovascular risk","Stroke","Cardiovascular death","Myocardial infarction","Atrial fibrillation","Ischemic heart disease","Major cardiovascular events","Acute Arterial events (i.e. pulmonary embolism)","NOT_YET_RECRUITING","2026-06-17",{"date":44,"type":45},"2026-06-23","ACTUAL",{"date":47,"type":22},"2026-09",{"date":49,"type":22},"2029-12",{"name":51,"class":52},"IRCCS Policlinico S. Donato","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100640884","structured-cardio-oncology-rehabilitation-for-cardiovascular-outcomes-in-cancer-survivors-100640884","NCT07622394","Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors","A Multicenter, Prospective, Parallel-Group, Superiority Randomized Controlled Trial of Structured Cardio-Oncology Rehabilitation for Improving Cardiovascular Outcomes in Patients With Cancer Therapy-Related Cardiac Dysfunction or High Cardiovascular Risk","CORE-CTRCD","Inclusion Criteria:\n\n* Age 18 years or older, regardless of sex.\n* Histologically or cytologically confirmed solid tumor or hematologic malignancy.\n* Completed curative anti-cancer therapy, or receiving stable adjuvant, maintenance, or palliative anti-cancer therapy.\n* Meets at least one criterion for cancer therapy-related cardiac dysfunction (CTRCD) or high cardiovascular risk, including reduced LVEF after anti-cancer therapy, high-dose anthracycline exposure, chest radiotherapy with cardiovascular risk factors, heart failure after anti-cancer therapy, or elevated cardiac injury\u002Fheart failure biomarkers.\n* Estimated life expectancy of at least 24 months as assessed by the treating oncologist.\n* Able to complete baseline cardiopulmonary exercise testing and has no absolute contraindication to exercise training.\n* Able and willing to provide written informed consent and comply with study intervention and follow-up.\n\nExclusion Criteria:\n\n* Active progressive malignancy requiring urgent anti-cancer therapy, or estimated life expectancy less than 24 months.\n* Severe structural heart disease, including severe valvular disease, congenital heart disease, end-stage heart failure, or waiting for heart transplantation or left ventricular assist device implantation.\n* Absolute contraindications to exercise training, including uncontrolled malignant arrhythmia, acute myocarditis or pericarditis, acute coronary syndrome within 2 weeks, severe anemia, severe thrombocytopenia or neutropenia, uncontrolled hypertension, active infection, or severe musculoskeletal disease preventing exercise training.\n* Participation in a structured cardiac rehabilitation program within the previous 12 months, or regular moderate-to-vigorous aerobic or resistance training for at least 3 months before enrollment.\n* Implanted ICD or CRT, except pacemakers with exercise mode.\n* Severe psychiatric disease or cognitive impairment preventing participation.\n* Concurrent participation in another interventional clinical trial, or planned participation in another interventional clinical trial during the study period.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","18 Months",{"count":63,"type":22},800,"INTERVENTIONAL",[66],"NA","Cancer therapy-related cardiac dysfunction (CTRCD) has become a major cause of morbidity and mortality among cancer survivors. Although cardiac rehabilitation is recommended for cardiovascular disease prevention and management, high-quality randomized controlled evidence regarding its efficacy in cardio-oncology populations remains limited.\n\nThis multicenter, prospective, parallel-group, superiority randomized controlled trial aims to evaluate whether a structured cardio-oncology rehabilitation (CORE) program combined with usual care can improve cardiovascular outcomes in patients with CTRCD or cancer survivors at high cardiovascular risk, compared with usual care alone.\n\nA total of 800 participants will be randomized in a 1:1 ratio to receive either structured cardio-oncology rehabilitation plus usual care or usual care alone. The intervention includes individualized exercise training, nutritional management, psychosocial support, cardiovascular risk-factor optimization, and patient education. Participants will be followed for 12 months.\n\nThe primary endpoint is time to first major adverse cardiovascular event (MACE) within 12 months. Secondary endpoints include changes in cardiorespiratory fitness, cardiac function, biomarkers, quality of life, physical function, psychological status, safety outcomes, and health economic outcomes.",[69,70,71,28,72],"Cancer Therapy-Related Cardiac Dysfunction","Cardio-oncology","Cancer Survivorship","Heart Failure",[74,75,76,77,78,79,80],"Structured Cardio-Oncology Rehabilitation","Cardiac Rehabilitation","Cancer Survivors","Major Adverse Cardiovascular Events","Exercise Training","Cardiorespiratory Fitness","CTRCD","2026-06-02",{"date":83,"type":45},"2026-06-03",{"date":85,"type":22},"2026-09-01",{"date":87,"type":22},"2029-09-30",{"name":89,"class":52},"Xinjiang Medical University",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":101,"conditions":102,"keywords":107,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":90},"100639968","cf-pwv-and-tyg-index-study-100639968","NCT07589374","Cf-PWV and TyG Index Study","Correlation Between Carotid-Femoral Pulse Wave Velocity and Triglyceride-Glucose Index and Its Derived Metrics","RIGID-TyG","Inclusion Criteria:\n\n* Adults aged 18 to 65 years;\n* Both sexes;\n* Referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation;\n* Not receiving antihypertensive medication at the time of assessment;\n* Availability of valid 24-hour ABPM data;\n* Availability of carotid-femoral pulse wave velocity (cf-PWV) measurement;\n* Availability of fasting laboratory data, including glucose and triglycerides, for calculation of the triglyceride-glucose (TyG) index;\n* Ability and willingness to provide written informed consent (for prospectively recruited participants).\n\nExclusion Criteria:\n\n* Use of antihypertensive medication at the time of evaluation;\n* Cardiac arrhythmias that may interfere with accurate blood pressure or pulse wave velocity measurements;\n* Invalid or poor-quality ambulatory blood pressure monitoring (ABPM) recordings;\n* Inability to obtain reliable carotid-femoral pulse wave velocity (cf-PWV) measurements;\n* Presence of severe vascular disease or conditions affecting arterial waveform assessment;\n* Missing essential clinical, laboratory, or hemodynamic data required for the primary analysis;\n* Pregnancy;\n* Refusal or inability to provide informed consent (for prospectively recruited participants).","65 Years",{"count":63,"type":22},"This study aims to investigate how metabolic health is related to arterial stiffness and daily blood pressure patterns. High blood pressure is one of the leading causes of heart disease worldwide, but cardiovascular risk is not determined only by average blood pressure values. Changes in blood vessel structure and metabolic function also play an important role in the development of cardiovascular disease.\n\nArterial stiffness reflects how flexible or rigid the arteries are. It can be measured using carotid-femoral pulse wave velocity (cf-PWV), which is considered a reliable and widely used method to assess vascular health. Increased arterial stiffness is associated with aging and higher cardiovascular risk.\n\nAt the same time, metabolic factors such as insulin resistance and central obesity are strongly linked to vascular damage. The triglyceride-glucose (TyG) index is a simple measure derived from routine blood tests and has been shown to reflect insulin resistance. Additional derived indices that combine TyG with body measurements (such as waist circumference and body mass index) may provide an even more comprehensive evaluation of metabolic risk.\n\nAnother important aspect of cardiovascular regulation is how blood pressure changes throughout the day. Blood pressure naturally rises in the morning after waking, a phenomenon known as the morning blood pressure surge. When this increase is excessive, it has been associated with a higher risk of cardiovascular events such as stroke and heart attack.\n\nThis study will evaluate the relationship between metabolic indices, arterial stiffness, and morning blood pressure patterns in adults undergoing ambulatory blood pressure monitoring as part of routine clinical care. The study will include both previously collected data and new participants evaluated using standardized methods.\n\nNo additional interventions will be performed, and all data will be collected as part of routine clinical evaluation. The results of this study may help improve cardiovascular risk assessment by integrating simple metabolic markers with vascular measurements and daily blood pressure behavior, potentially allowing earlier identification of individuals at higher risk.",[103,104,105,28,106],"Hypertension","Insulin Resistance Syndrome","Arterial Stiffness","Blood Pressure Variability",[108,109,110,111,112,113,114,33],"Arterial stiffness","Pulse wave velocity","Triglyceride-glucose index","Insulin resistance","Ambulatory blood pressure monitoring","Morning blood pressure surge","Blood pressure variability","2026-05-19",{"date":117,"type":45},"2026-05-22",{"date":119,"type":22},"2026-07-01",{"date":121,"type":22},"2028-07-01",{"name":123,"class":52},"Hospital de Base",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":64,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":150},"100525172","phase-3-artemis---a-research-study-to-look-at-how-ziltivekimab-works-compared-to-placebo-in-people-with-a-heart-attack-100525172","NCT06118281","ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack","ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction","ARTEMIS","Key inclusion:\n\n* Age 18 years or above at the time of signing the informed consent.\n* Hospitalisation for acute myocardial infarction with evidence of type 1 myocardial infarction (MI) by invasive angiography performed at site with percutaneous coronary intervention (PCI) capabilities.\n* ST-segment elevation myocardial infarction (STEMI) with all the following: a) Relevant onset of symptoms suggestive of cardiac ischaemia within 12 hours before hospitalisation, at the investigator's discretion.\n\n  b) Electrocardiogram (ECG)-changes (in the absence of left ventricular hypertrophy or left bundle branch block): ST-segment elevation at the J point in at least two contiguous leads greater than or equal 0.25 (millivolt) mV in men less than 40 years, greater than or equal 0.2 mV in men greater than or equal 40 years, or greater than or equal 0.15 mV in women in leads V2-V3; and\u002For greater than or equal 0.1 mV in all other leads.\n\nOR\n\n* Non-ST-segment myocardial infarction with all the following: a) Relevant onset of symptoms suggestive of cardiac ischaemia within 24 hours before hospitalisation, at the investigator's discretion. b) Rise and\u002For fall in car-diac troponin I or T with at least one value above the 99th percentile upper reference limit.\n* Possibility for both randomisation and administration of the loading dose of study intervention as early as possible after invasive procedure, and latest within 36 hours of hospitalisation (time 0) for STEMI, and latest within 72 hours of hospitalisation (time 0) for NSTEMI.\n* Presence of at least one of the following criteria confirmed based on the participant's medical records and\u002For medical history interview: a) Any prior MI. b) Prior coronary revascularisation. c) Diabetes mellitus treated with ongoing glucose-lowering agent(s). d)Known chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) greater than or equal to 15 and less than 60 milliliter per minute per 1.73 square meter (mL\u002Fmin\u002F1.73 m\\^2). e) Prior ischaemic stroke. f) Known carotid disease or peripheral artery disease in the lower extremities. g) Multivessel coronary artery disease (current\u002Fprior). h) For STEMI patients only: anterior MI at index acute myocardial infarction (AMI)\n\nKey exclusion:\n\n* Use of fibrinolytic therapy for treatment of the current AMI.\n* Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV.\n* Ongoing haemodynamic instability defined as any of the following: a) Killip Class III or IV. b) Sustained and\u002For symptomatic hypotension (systolic blood pressure less than 90 millimeters of mercury (mmHg)).\n* Severe kidney impairment defined as any of the following: a) eGFR less than 15 mililitre per minute per 1.73 m\\^2. b) Chronic haemodialysis or peritoneal dialysis.\n* Known alanine aminotransferase (ALT) greater than 8 x upper limit of normal (reference range) (ULN).\n* Severe hepatic disease defined as at least one of the following: a) Previously known or current hepatic encephalopathy (clinical evaluation). b) Previously known or current ascites (clinical eval-uation). c) Jaundice (clinical evaluation). d) Previous oesophageal\u002Fgastric variceal bleeding. c) Known hepatic cirrhosis.\n* Major cardiac surgical (including but not restricted to coronary artery bypass graft surgery (CABG)), non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days or any major surgical procedure planned at the time of randomisation or as treatment for the current AMI (CABG). Deferred (staged)percutaneous coronary intervention for a non-culprit vessel identified during the current AMI is allowed.\n* Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.\n* Known (acute or chronic) hepatitis B or hepatitis C.\n* History or evidence of untreated latent tuberculosis (TB) such as (but not limited to): a) History of a positive TB test or chest X-ray compatible with latent TB; and TB treatment initiated less than 28 days prior to randomisation. b) Participants with TB risk factors but unwilling to undergo TB treatment if confirmed positive for latent TB based on central laboratory test at baseline (visit 2).",{"count":133,"type":22},10000,[135],"PHASE3","The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.",[28,138],"Acute Myocardial Infarction (AMI)","RECRUITING","2026-04-12",{"date":142,"type":45},"2026-04-14",{"date":144,"type":45},"2024-06-25",{"date":146,"type":22},"2026-12-14",{"name":148,"class":149},"Novo Nordisk A\u002FS","INDUSTRY",970,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":64,"phases":160,"briefSummary":161,"conditions":162,"keywords":169,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":90},"100628633","evolution-of-hypoxic-burden-and-sympatheticparasympathetic-balance-in-patients-with-pulmonary-hypertension-100628633","NCT07464184","Evolution of Hypoxic Burden and Sympathetic\u002FParasympathetic Balance in Patients With Pulmonary Hypertension","HRV&PH","Inclusion Criteria:\n\n* Patients over 18 years of age\n* With precapillary pulmonary hypertension confirmed by pulmonary artery catheterization\n* With an indication for pulmonary artery vasodilator treatment\n* Affiliation with a social security system\n* Women of childbearing age using effective\u002Fhighly effective contraception (see CTFG) (estrogen-progestogen or intrauterine device or tubal ligation) for 6 months and a negative urine pregnancy test at inclusion, for the duration of the study.\n* Postmenopausal women: confirmed diagnosis (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit)\n* Individuals who have read and understood the information letter and signed the consent form\n\nNon-Inclusion Criteria:\n\n* Treatment with non-invasive ventilation\n* Eisenmenger syndrome\n* Systemic scleroderma\n* Neurodegenerative disease other than isolated peripheral neuropathies.\n* Untreated and\u002For uncontrolled cardiac rhythm or conduction disorders, including permanent AF\n* Untreated coronary artery disease or diagnosis of myocardial infarction within the last six months\n* Pacemaker wearer\n* Pregnant or breastfeeding women, or women who are not using reliable contraception\n* Persons deprived of their liberty by administrative or judicial decision or persons under judicial protection\u002Fguardianship or curatorship\n* History of psychological or sensory illness or abnormality that may prevent the subject from fully understanding the conditions required for participation in the protocol or prevent them from giving their informed consent",{"count":159,"type":22},60,[66],"Background and Rationale:\n\nSleep-disordered breathing and nocturnal hypoxemia are highly prevalent in patients with precapillary pulmonary hypertension (PH), and current guidelines recommend systematic sleep assessment in this population. In obstructive sleep apnea, nocturnal hypoxic burden-defined as the area under the SpO₂ desaturation curve associated with respiratory events (%.min\u002Fh)-has demonstrated strong prognostic value for cardiovascular morbidity and mortality. However, its role in precapillary PH has not yet been investigated. Evaluating hypoxic burden in this population may refine indications and therapeutic targets for nocturnal oxygen therapy.\n\nIn addition, pulmonary hypertension is characterized by autonomic nervous system (ANS) dysfunction, including increased sympathetic tone, reduced heart rate variability (HRV), and a higher incidence of cardiac arrhythmias, all associated with worse prognosis. The reduction in HRV is particularly deleterious when occurring during restorative slow-wave sleep (N3), a phase marked by predominant parasympathetic activity essential for cardiovascular recovery and homeostasis. A better understanding of the interaction between nocturnal hypoxemia and ANS modulation may provide new prognostic markers and potential therapeutic targets in PH.\n\nObjectives:\n\n1. To describe the evolution of nocturnal hypoxic burden over time in patients with precapillary pulmonary hypertension (at baseline, 12 months, and 24 months).\n2. To describe the longitudinal evolution of HRV parameters (RMSSD, LF\u002FHF ratio, HF) at baseline, 12 months, and 24 months.\n3. To evaluate cross-sectional correlations (at baseline, M12, and M24) between HRV parameters, hypoxic burden, oxygen desaturation, apnea-hypopnea index (AHI), and clinical status.\n4. To evaluate longitudinal correlations between changes in HRV parameters, hypoxic burden, desaturation, AHI, and clinical status between baseline and M12, and between baseline and M24.\n5. To assess the 2-year prognostic value of HRV parameters and hypoxic burden for adverse clinical outcomes.\n\nStudy Design and Population:\n\nThis is a prospective, single-center observational cohort study conducted at the Pulmonary Hypertension Referral Center of Rouen University Hospital. The cohort design allows longitudinal assessment of HRV, hypoxic burden, and clinical status, enabling both cross-sectional and longitudinal correlation analyses, as well as prognostic evaluation. A total of 60 adult patients (≥18 years) with precapillary pulmonary hypertension confirmed by right heart catheterization and requiring pulmonary arterial vasodilator therapy will be included.\n\nParticipants will undergo full overnight polysomnography (PSG) at:\n\n* Baseline (inclusion)\n* 12 months (M12)\n* 24 months (M24) For incident cases, baseline PSG will be performed prior to initiation of vasodilator therapy. All patients will continue to receive standard-of-care management according to current European guidelines for pulmonary hypertension.\n\nDescriptive analyses and cross-sectional correlations will pool repeated measures (excluding incident baseline values for generalization to prevalent cases). Intra-subject correlation will be accounted for using bootstrap methods. Longitudinal analyses will assess changes over time and prognostic associations. The prognostic value of HRV and hypoxic burden will be evaluated over a 2-year follow-up period. This study explores an original dimension of precapillary pulmonary hypertension pathophysiology by investigating the interaction between nocturnal oxygenation, autonomic dysfunction, and clinical evolution. Identification of hypoxic burden and HRV as prognostic markers may contribute to improved risk astratification and therapeutic optimization in this high-risk population.",[163,164,165,166,167,168,28],"Precapillary Pulmonary Hypertension","Pulmonary Arterial Hypertension","Sleep-disordered Breathing","Nocturnal Hypoxemia","Autonomic Nervous System Dysfunction","Heart Rate Variability (HRV)",[170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186],"Precapillary pulmonary hypertension","Pulmonary arterial hypertension","Hypoxic burden","Nocturnal hypoxia","Polysomnography","Sleep-disordered breathing","Heart rate variability (HRV)","RMSSD","LF\u002FHF ratio","High frequency","Autonomic nervous system","Sympathetic activation","Parasympathetic tone","Risk stratification","Prognostic markers","Right heart failure","Apnea-Hypopnea Index (AHI)","2026-04-10",{"date":189,"type":45},"2026-04-15",{"date":191,"type":22},"2026-06-01",{"date":193,"type":22},"2030-01-01",{"name":195,"class":52},"University Hospital, Rouen",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":64,"phases":205,"briefSummary":206,"conditions":207,"keywords":212,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":90},"100629762","impact-of-the-corrie-lipids-digital-health-program-on-lipid-optimization-100629762","NCT07478887","Impact of the Corrie Lipids Digital Health Program on Lipid Optimization","Corrie Lipids Program: Optimizing LDL-Cholesterol by Improving Awareness, Access, and Achievement","Inclusion Criteria:\n\n* Age ≥18 years\n* Uncontrolled LDL-C per AHA\u002FACC guidelines\n* At least 1 major cardiovascular risk factor, including: high risk for ASCVD (individuals who meet criteria for Lipid-Lowering Therapy (LLT) based on ASCVD risk assessment using the most up-to-date guidelines), known ASCVD or subclinical ASCVD based on imaging, clinically diagnosed familial hypercholesterolemia or LDL-C ≥190 mg\u002FdL, diabetes mellitus, history of statin-associated side effects\n* Has a primary care physician and\u002For cardiologist who can prescribe lipid therapy\n* Owns a smartphone and agrees to the End User License Agreement to use the digital health app\n* Provided informed consent before initiation of study-specific activities\n\nExclusion Criteria:\n\n* Motor, cognitive, auditory, or visual impairment limiting technology use\n* Does not speak English\n* Malignancy (except nonmelanoma skin cancers or cervical or breast ductal carcinoma in situ within the previous 5 years)\n* Pregnancy (positive pregnancy test, highly sensitive urine or serum), plan to become pregnant or donate eggs, breastfeeding or plan to breastfeed\n* Likely to not be available to comply with all required study procedures to the best of the patient's and investigator's knowledge\n* History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion",{"count":204,"type":22},1000,[66],"The overall objective is to evaluate the effectiveness and implementation of the Corrie Lipids Program, a comprehensive digital health initiative designed to address critical gaps in lipid-lowering as a component of ASCVD treatment by delivering an intervention that combines a patient-facing smartphone app, clinician education and coaching, and seamless incorporation into clinical workflows.\n\nResearchers plan to assess this multicenter digital health initiative in approximately 1,000 adults with uncontrolled LDL-C and elevated ASCVD risk using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. The study will examine whether the program improves LDL-C goal attainment, app engagement, prescribing patterns, and LDL-C monitoring, while also identifying barriers and facilitators to implementation across sites.",[28,208,209,210,211],"LDL-C","Lipids","Digital Health","Implementation Science",[213,214],"Apolipoprotein B (apoB)","Lipoprotein-a (Lp(a)","2026-03-13",{"date":217,"type":45},"2026-03-18",{"date":219,"type":45},"2025-06-20",{"date":221,"type":22},"2027-12",{"name":223,"class":52},"Johns Hopkins University",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":90},"100624655","guideline-adherence-in-dyslipidemia-with-clinical-decision-support-100624655","NCT07412457","Guideline Adherence in Dyslipidemia With Clinical Decision Support","Assessment of Adherence to Clinical Practice Guidelines in Patients With Dyslipidemia Using a Clinical Decision Support System","Inclusion Criteria:\n\n1. Availability of the required amount of patient data for completion of the questionnaire-based system;\n2. Age 18 years or older;\n3. Signed informed consent to participate in the study.\n\nNon-inclusion criteria:\n\n1. Patients with insufficient data to complete the questionnaire;\n2. Refusal to sign informed consent for participation in the study.\n\n   Exclusion Criteria:\n3. Absence of a consensus opinion on the clinical case among two of the three experts.",{"count":232,"type":22},500,"Objective: To validate the performance of the developed clinical decision support system (CDSS) for participants with lipid metabolism disorders based on a decision tree algorithm.\n\nMaterials and Methods: A clinical decision support system for participants with lipid profile abnormalities will be developed using the Orbeon open-source online form creation platform based on current clinical guidelines.\n\nDuring the CDSS pilot implementation, the electronic medical records (EMRs) of 500 participants from the Institute of Personalized Cardiology of the Biomedical Science and Technology Park at Sechenov University will be analyzed.\n\nRetrospective data on prescribed lipid-lowering therapy extracted from the EHR will be compared with the CDSS recommendations. The accuracy of the decisions will be assessed by three independent experts based on digitized clinical and laboratory patient profiles.\n\nThe primary endpoint of the study will be to determine the accuracy of the system.\n\nResults: This study will result in the development (creation) and pilot application of the CDSS program in participants with dyslipidemia in real clinical practice.\n\nConclusion: The developed CDSS system for dyslipidemia will significantly reduce the time required for clinical decision-making and help avoid errors in the interpretation of patient data.",[235,236,237,28,238],"Dyslipidemia","Coronary Artery Disease","Atherosclerosis of Major Arteries","Subclinical Atherosclerosis",[240,241,242,243],"dyslipidemia","atherosclerosis","revascularization","cardiovascular risk","2026-02-22",{"date":246,"type":45},"2026-02-24",{"date":248,"type":22},"2026-04-01",{"date":250,"type":22},"2027-09-30",{"name":252,"class":52},"I.M. Sechenov First Moscow State Medical University",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":18,"minAge":260,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":263,"conditions":264,"keywords":273,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":294},"100580429","studying-the-presence-of-cfrd-complications-with-thoughtful-recruitment-spectrum-100580429","NCT06837181","Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)","SPeCTRuM","Inclusion Criteria:\n\n* Written informed consent (and assent when applicable) obtained from participant or participant's legally authorized representative\n* For Adults: Must be able to consent on one own's behalf (i.e., cannot lack cognitive capacity to consent due to the required patient-reported outcomes)\n* Be willing and able to adhere to the study protocol requirements\n* Age ≥ 12 years at time of enrollment\n* CF diagnosis based on two CF causing mutations and\u002For positive sweat test according to CFF diagnostic criteria\n* CFRD diagnosis ≥ 5 years at time of enrollment\n\nExclusion Criteria:\n\n* History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject\n* History of transplant\n* Pregnancy reported by participant at time of consent or at any point during active study participation\n\nPulse Wave Velocity Exclusion Criteria:\n\n* Erratic, accelerated or mechanically controlled irregular heart rhythms including arrhythmias\n* Carotid or aortic valve stenosis\n* Peripheral artery disease or leg artery disease\n* Generalized constriction or localized spasm of muscular conduit arteries such as seen immediately after hypothermic cardiopulmonary bypass surgery or accompanying Raynaud's phenomena or intense cold.\n* Possible exclusions based on investigator medical provider assessment (additional precautions may be followed to allow inclusion):\n\n  * Pressure reading should not be conducted on a limb where there is intravenous access, arterio-venous shunt, or where circulation is compromised.\n  * Pressure reading should not be conducted on the side of the body that a mastectomy was done.","12 Years",{"count":262,"type":22},200,"This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF.\n\nThe overall Aim is to describe prevalence of diabetes microvascular complications and macrovascular surrogates in people with established CFRD.",[265,266,267,268,269,270,271,28,272],"Cystic Fibrosis (CF)","Cystic Fibrosis-related Diabetes","Diabetes","Retinopathy","Neuropathy","Nephropathy","Blood Pressure","Microvascular",[274,275,276,277,278,279,280,267,281,243,282,283,284],"Cystic Fibrosis","CFRD","Cystic Fibrosis-Related Diabetes","Observational","Physical Activity Tracker","Continuous glucose monitoring","CGM","blood pressure","microvascular","diabetes complications","social determinants of health","2026-02-09",{"date":287,"type":45},"2026-02-10",{"date":289,"type":45},"2025-09-18",{"date":291,"type":22},"2028-11-30",{"name":293,"class":52},"Jaeb Center for Health Research",18,{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":17,"sex":18,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":64,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":320,"locationsCount":321},"100580080","novel-risk-prediction-approaches-for-the-primary-prevention-of-cardiovascular-diseases-in-italy-the-cvrisk-it-trial-cvrisk-it-100580080","NCT06832644","Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial (CVRISK-IT)","Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial","CVRISK-IT","Inclusion Criteria:\n\n* Age: 40-80 years\n* Apparently healthy individuals without previous medical history of CVD or diabetes (based on medical diagnosis)\n* Participant recruitment arranged only at selected IRCCS (and associated Spokes) as part of the 'Rete Cardiologica'\n* Participants must have signed the Informed Consent and Data Privacy Treatment forms\n* Participants must have a personal e-mail address and internet connection\n\nExclusion Criteria:\n\n* Age ≤40 or ≥80 years\n* Individuals have previous medical history related to CVD (e.g., heart failure, congenital heart disorder, coronary heart disease) based on medical diagnosis\n* Candidates have previously participated in clinical studies of 'Rete Cardiologica' (e.g., PREVITAL)\n* Medical diagnosis of mental disorders\n* Pregnancy based on self-reported information\n* Previous history of type 1 or type 2 diabetes (based on medical diagnosis)\n* Oncology patients (based on physician indication)","40 Years","80 Years",{"count":306,"type":22},30000,[66],"The CVRISK-IT study aims to evaluate the health benefit of measuring genetic and imaging risk information in men and women considered at 'low-to-moderate' or 'high' risk of developing cardiovascular diseases (CVD) in a randomized controlled trial in Italian primary care settings. Our primary objective is to answer a fundamental question in the prevention and prediction of CVD in Italy and globally: is there any benefit in including additional information (such as genetic and\u002For imaging data) in estimating risk, in conjunction with lifestyle advice and medical treatment for primary prevention of CVD?\n\nAs a key secondary objective of the CVRISK-IT study, the goal is to build a large bioresource with clinical information and biological samples to facilitate a new generation of discovery and translational research that will advance understanding of the genetic, molecular and behavioural determinants as well as mechanisms of multiple chronic diseases in the Italian population. By contributing to the Rete Cardiologica database and the BBDCARDIO biobank, the CVRISK-IT study will also serve as a cornerstone for future investigations into the development and testing of early diagnostic technologies and preventive (or 'personalised precision health') interventions for chronic diseases.",[28,310],"Genetic Cardiovascular Risk",[312,28,313],"Primary Prevention","SCORE2\u002F2-OP","2026-01-12",{"date":316,"type":45},"2026-01-14",{"date":318,"type":45},"2025-01-22",{"date":193,"type":22},{"name":51,"class":52},17,{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":329,"minAge":330,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":64,"phases":334,"briefSummary":335,"conditions":336,"keywords":340,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":90},"100612888","time-restricted-eating-in-survivors-trial-20-100612888","NCT07259434","Time Restricted Eating in Survivors Trial 2.0","TEST2","Inclusion Criteria:\n\n* female\n* aged 60-85 years\n* BMI ≥25 kg\u002Fm2\n* diagnosed with early-stage (I-III) BC in the past 15 years\n* received chemotherapy treatment that was completed ≥1 year earlier\n* Montreal Cognitive Assessment (MoCA) score of 10-30 which aligns with no impairment to moderate impairment thresholds.\n\nExclusion Criteria:\n\n* does not have a mobile device that connects to Bluetooth and can send\u002Freceive text messages\n* history of physician-diagnosed heart disease, dementia or Alzheimer's disease, diabetes that requires insulin or sulfonylurea usage, or eating disorder\n* MoCA total score \\\u003C10 (indicating dementia)\n* ≥5kg weight change within past 3 months\n* taking lipid- or weight-lowering medication (e.g. statins or GLP-1 agonists)\n* high-risk for malnutrition (≥3 on the Malnutrition Screening Tool)\n* research MRI contraindications (e.g., pacemaker, breast tissue expander, magnetic implants)\n* eating all daily calories in \\\u003C10h\u002Fd in the past 3 months\n* following a structured dietary practice (e.g., ketogenic diet, Weight Watchers) or actively trying to lose weight in the past 3 months\n* being unable to make adjustments to eating time or nutrient intake\n* regularly doing \\>90 min\u002Fweek of moderate physical activity in the past 3 months\n* severe claustrophobia\n* BMI\\>40 kg\u002Fm2 (due to body habitus fit within MRI scanner bore)\n* major psychiatric disorders (e.g. bipolar, post-traumatic stress disorder, schizophrenia)\n* neurological disorders that significantly impact physical or cognitive function (epilepsy, stroke, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, muscular dystrophy) or traumatic brain injury resulting in ongoing neurological deficits. If the screening process identifies patients with undiagnosed severe cognitive function (MoCA score \\\u003C10) or at high risk for malnutrition (≥3 on the Malnutrition Screening Tool), the investigators will recommend that the individual see their family physician. In this process, the investigators will ask the participant if there is a family member that can also receive this information.","FEMALE","60 Years","85 Years",{"count":333,"type":22},152,[66],"After chemotherapy, older breast cancer survivors experience a faster decline in brain function. This can make it harder to enjoy life, stay social, and maintain independence. Chemotherapy can lead to poorer lifestyle habits, like unhealthy eating, less exercise, high stress, and poor sleep. Chemotherapy can also affect important health markers like blood sugar and cholesterol. Over time, these changes can damage blood vessels, which might lead to heart and brain issues. The investigators do not fully understand why brain function declines faster after chemotherapy, especially in older survivors, because there are many factors involved. In this study, the investigators will look at how lifestyle habits (like diet, exercise, stress and sleep), health markers (like blood sugar and cholesterol), and blood vessel health (like how well blood flows and how stiff the blood vessels are) affect brain function in older breast cancer survivors. The investigators will include 152 females aged 60-85 years, who finished chemotherapy for early-stage breast cancer at least 1 year ago. The investigators will use special tests to check different parts of brain function, like language, memory, and attention, as well as brain blood vessel health. This will help to understand which factors might speed up or slow down memory and thinking problems. Since many Canadian breast cancer survivors experience faster decline in brain function after chemotherapy, this study aims to find out what might make it worse. The results could help to create better and more personalized treatment plans for older breast cancer survivors that protect brain health and reduce problems with brain function in the future.",[337,28,338,339],"Breast Cancer","Cognitive Function","Physical Function",[341,342],"Treatment","Prevention","2025-11-20",{"date":345,"type":45},"2025-12-02",{"date":347,"type":22},"2026-01-01",{"date":349,"type":22},"2028-10-31",{"name":351,"class":52},"University of Toronto",{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":18,"minAge":303,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":64,"phases":361,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":372,"locationsCount":90},"100563690","dose-response-to-resistance-exercise-on-cardiovascular-health-100563690","NCT06619444","Dose-Response to Resistance Exercise on Cardiovascular Health","DoReps","Inclusion Criteria:\n\n* Non-Smoker\n* Overweight or Obese: Body Mass Index 25-43 kg\u002Fm2\n* Inactive: not meeting the US resistance and aerobic exercise guidelines over the last 6 months\n* Walking \\\u003C7,000 steps\u002Fday at baseline\n* Capable of performing the required exercise training\n\nExclusion Criteria:\n\nAbsolute\n\n* Unstable coronary heart disease or heart failure\n* Uncontrolled arrhythmias or severe aortic stenosis\n* Acute myocarditis, endocarditis, or pericarditis\n* Cancer, requiring treatment in the past 5 years\n* Autoimmune diseases, affecting immune system\n* Plans to be away ≥4 weeks in the next 1 year\n* Pregnancy\u002Fanticipated pregnancy during the study\n* Other medical condition that is life-threatening or can interfere with or be aggravated by the exercise training\n* Uncontrolled Diabetes (HbA1c ≥8.0),\n* Hypertensive Blood Pressure ≥160 mm Hg Systolic and\u002For 100 mm Hg Diastolic,\n\nRelative (should consult a physician)\n\n* Major risk factors for coronary heart disease\n* Uncontrolled diabetes or musculoskeletal limitations",{"count":360,"type":22},240,[66],"A large body of evidence indicates numerous health benefits of physical activity, including prevention of cardiovascular disease (CVD), the leading cause of death in the US. This evidence has led to US Physical Activity Guidelines that recommend ≥150 min\u002Fweek of moderate or ≥75 min\u002Fweek of vigorous aerobic exercise (AE), plus resistance exercise (RE; such as weight lifting) on ≥2 days\u002Fweek. To date, current research has mostly focused on AE, and we know a great deal about the dose-response relation between AE and health, resulting in clear and practical guidance to the public on the recommended \"dose\" in min\u002Fweek. However, currently far less is known about the dose-response for RE: ≥2 days\u002Fweek are recommended, but with no duration specified. Thus, this project aims to provide clarity on the dose relationship between RE and health. This project will significantly contribute to developing more effective CVD prevention approaches, advancing prescriptive intervention guidelines, by helping to fill the important gaps in knowledge on effective minimum dose, beneficial optimal dose, and safe maximum dose of RE for CVD prevention. Thus, advancing prescriptive intervention guidelines, and provide important insights for future science of physical activity and health.",[28],[365],"Exercise","2025-08-07",{"date":368,"type":45},"2025-08-12",{"date":370,"type":45},"2024-12-03",{"date":221,"type":22},{"name":373,"class":52},"University of Pittsburgh",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":17,"sex":18,"minAge":382,"maxAge":331,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":397,"leadSponsor":399,"locationsCount":401},"100567629","evaluation-of-the-clinical-benefit-of-the-aktiia-blood-pressure-monitoring-for-early-awareness-of-hypertension-and-prediction-of-cardiovascular-risk-100567629","NCT06670677","Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk","OBPM_FORESEE2024: Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk in a Multi-ethnic European Population: an Observational Cohorts' Study","FORESEE2024","Inclusion Criteria:\n\n1. Adult subjects aged 21 to 85 years old\n2. Subjects living in Switzerland, Germany or in the UK\n3. Subjects that are:\n\n   Aktiia users owning a smartphone with either iOS or Android operating system (ARMs 1 and 2); or Aktiia non-users owning a smartphone with iOS or Android operating system (ARM 3)\n4. Subjects agreeing to follow the study procedures.\n\nExclusion Criteria:\n\n1. Subjects suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including resting tachycardia (heart rate at rest \\> 120bpm) and atrial fibrillation;\n2. Subjects suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR \\\u003C 30mL \u002F min \u002F 1.73 m2), untreated hyper-\u002F hypothyroidism, pheochromocytoma, or arteriovenous fistula;\n3. Subjects suffering from polyneuropathy;\n4. on pregnant women;\n5. Subjects with damaged \u002F injured skin at the wrists (for bracelet measurements) or at index fingers (for camera measurements)\n6. Subjects with amputated index fingers (for camera measurements) or amputated upper limb;\n7. Subjects below 21 years old and above 85 years old.","21 Years",{"count":384,"type":22},15000,"Because Aktiia S.A. has been the first-ever company to put in the market an Optical Blood Pressure Monitoring device, there is a need for Aktiia S.A. to correlate for the first time continual Blood Pressure monitoring and the evolution of environmental and health factors to improve hypertension management.",[103,28,387],"Blood Pressure Check (Hypertension Screening)",[389,281,390,391,243,392],"hypertension","Hypertensive","cardiovascular diseases","prediction","2025-05-12",{"date":395,"type":45},"2025-05-14",{"date":393,"type":45},{"date":398,"type":22},"2035-05-31",{"name":400,"class":149},"Aktiia SA",2,{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":409,"minAge":19,"maxAge":304,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":90},"100528680","the-effect-of-multidisciplinary-care-approach-on-cv-risk-modification-in-cap-patients-receiving-adt-100528680","NCT06163924","The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT","To Investigate the Effect of Multidisciplinary Care Approach on Cardiovascular Risk Modification in Prostate Cancer Patients Receiving Androgen Deprivation Therapy","Inclusion Criteria:\n\n* Adult men 18-80 years old\n* With histological proven prostate cancer or clinically diagnosed to have prostate cancer,\n* Planned for ADT for at least 1 year\n\nExclusion Criteria:\n\n* Subjects with established major atherosclerotic cardiovascular disease (ASCVD) as defined by a recent acute coronary syndrome within the past 12 months, a history of myocardial infarction other than the recent acute coronary syndrome event, a history of ischemic stroke, and symptomatic peripheral arterial disease (defined as history of claudication with ankle-brachial index \\<0.85 or previous revascularization or amputation\n* Prior neoadjuvant or adjuvant hormone therapy within 1 year before\n* Refuse or unable to give written informed consent\n* Participation in an investigational program with interventions outside of routine clinical practice","MALE",{"count":411,"type":22},130,"Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%. While ADT can effectively control disease, there is increasing evidence suggesting that it can also result in many adverse cardiovascular side effects on the patients, and these effects are particularly important due to the prolonged survival of these patients. There are suggestions that close cardiovascular (CV) monitoring will help to reduce cardiovascular risk and related morbidities. However, there is limited data to show the positive impact of these monitoring could reducing CV risk and morbidities. Moreover, information regarding the optimal follow-up approach and schedule is also lacking. Therefore, there is a need to have more information on the approach to monitoring the CV risk and the real-life impact of this monitoring on our patients. Patients diagnosed with prostate cancer and plan to receive ADT are invited to participate in this study to assess the potential benefit of multidisciplinary care approach to CV risk modification.",[28,414],"Prostate Cancer",[414,416],"Androgen deprivation Therapy","2025-05-04",{"date":419,"type":45},"2025-05-06",{"date":421,"type":45},"2023-12-10",{"date":423,"type":22},"2029-03-31",{"name":425,"class":52},"Chinese University of Hong Kong",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":436,"conditions":437,"keywords":440,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":4},"100578451","suicide-ideation-in-hereditary-angioedema-100578451","NCT06811467","Suicide Ideation in Hereditary Angioedema","Suicidal Ideation in Hereditary Angioedema","HAE-SAFE","Inclusion Criteria:\n\n* Confirmed diagnosis of hereditary angioedema\n* Over the age of 18\n\nExclusion Criteria:\n\n* Patients with intellectual disability\n* Refusal to participate in the study\n* Patients with acquired C1-INH deficiency\n* Patients with other dermatological diseases.",{"count":435,"type":22},100,"This study focuses on patients with Hereditary Angioedema (HAE) to better understand how mental health affects overall well-being. Through a questionnaire, the investigators will assess the presence of suicidal thoughts, anxiety, and depression, as well as cardiovascular risk markers. By analyzing these factors together, the investigators aim to identify possible links between mental health and heart health in people with HAE. This research will help improve care strategies and highlight the importance of mental well-being in managing HAE.",[438,439,28],"Hereditary Angioedema (HAE)","Suicidal Ideation",[441,442,443,243],"Hereditary Angioedema","Suicidal ideation","TyG-BMI","2025-02-06",{"date":446,"type":45},"2025-02-10",{"date":448,"type":22},"2025-03-01",{"date":450,"type":22},"2025-09",{"name":452,"class":52},"Ivan Cherrez Ojeda",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":460,"enrollmentInfo":461,"targetDuration":4,"studyType":64,"phases":463,"briefSummary":464,"conditions":465,"keywords":469,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":90},"100574380","coffee-bioequivalence-trial-100574380","NCT06758531","Coffee Bioequivalence Trial","Coffee Bioequivalence Trial: Comparing the Pharmacokinetics of Bioactive Components and Physiological Effects of Consuming Encapsulated Instant Coffee Versus Traditional Instant Coffee Brewed in Water","Inclusion Criteria:\n\n* Healthy males and pre-menopausal females (must have regular menstrual cycles)\n* Aged between 18 to 45 years\n* Body mass index (BMI) between 18.5-30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Sensitivity to coffee and caffeine\n* Food allergies relating to the test meals provided (such as gluten or lactose intolerance)\n* Current smoking and vaping use.\n* Medical history of chronic diseases (cancer, high blood pressure (hypertension), type 2 diabetes, heart attack and\u002For any other heart disease related diseases, gastrointestinal disorders, hyperlipidaemia, kidney or liver disease).\n* Diagnosed with anaemia\n* Prescribed any medication relating to the study outcome measures (such as blood pressure lowering, anti-inflammatories or blood thinners).\n* Drinking more than the recommended intake for alcohol (\\> 14 units\u002Fweek)\n* Taking any supplements (vitamins, minerals, probiotics).\n* Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study (e.g. pacemaker)\n* Planning on a weight-reducing regimen (lost \\>3 kg in the last 6 months)\n* Parallel participation in another intervention study\n* Pregnancy, planning a pregnancy in the next 6 months or breastfeeding\n* NHS blood donation in the last 3 months","45 Years",{"count":462,"type":22},16,[66],"The goal of this clinical trial is to test if coffee consumed as a tablet is biologically equivalent to that consumed traditionally as a drink. It will also learn about the impact of the short-term intake of coffee on markers of cardiovascular and liver health. The main questions it aims to answer are:\n\n* Do coffee bioactive compounds produce the same levels in blood and urine regardless of how the coffee is consumed (tablet or drink)?\n* How does coffee as a tablet or drink impact cardiovascular risk and liver health versus a non-coffee control?\n\nParticipants will:\n\n* Visit the clinical unit for three phases; each phase is 1x 480 minute (eight hour) acute postprandial visit and 1 x one hour visit the following day. During each phase they will be randomly assigned to take a different intervention (coffee drink, coffee tablet, coffee-free control)\n* Be cannulated during the 480 minute (8 hour) acute visits and have regular blood draws as well as basic clinical assessments\n* Return on day two for a fasting blood sample and basic clinical assessment\n* Collect their urine for 24 h\n* Be asked to record their intake of foods and drinks for 3 days to assess their usual diet (dietary assessment).",[466,467,28,468],"Liver Functions","Bioequivalence","Cardiometabolic Risk Markers",[470,467,471,472,473,474,475,476],"Coffee","Caffeine","Liver function","Polyphenols","Blood pressure","Cardiovascular disease","Chlorogenic acids","2025-01-02",{"date":479,"type":45},"2025-01-03",{"date":481,"type":22},"2025-01",{"date":483,"type":22},"2025-12-30",{"name":485,"class":52},"University of Reading",{"id":487,"slug":488,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":64,"phases":496,"briefSummary":497,"conditions":498,"keywords":502,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":508,"leadSponsor":510,"locationsCount":90},"100574286","impact-of-mediterranean-diet-in-cardiovascular-risk-among-people-with-hiv-100574286","NCT06757309","Impact of Mediterranean Diet in Cardiovascular Risk Among People With HIV","Randomized Study to Evaluate the Impact of Dietary Optimization on Metabolic Profile, Immunoactivation and Cardiovascular Risk in HIV Population on ART","VIHMED","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Confirmed diagnosis of HIV infection.\n* On stable antiretroviral therapy (ART) with an undetectable viral load for at least 12 months.\n* LDL cholesterol levels \\>140 mg\u002FdL.\n* Low adherence to the Mediterranean diet, defined by a MEDAS score \\\u003C9.\n* Must be able to swallow tablets\n* Willingness and ability to provide informed consent.\n\nExclusion Criteria:\n\n* Use of lipid-lowering medications.\n* Chronic use of anti-inflammatory drugs.\n* Active hepatitis B or hepatitis C infection.\n* Other chronic inflammatory conditions (e.g., autoimmune diseases).\n* Familial hypercholesterolemia.\n* Uncontrolled metabolic conditions, such as hypothyroidism or diabetes mellitus.\n* Pregnancy or breastfeeding.\n* Cognitive or psychological conditions impairing the ability to comply with the study protocol.\n* Inability to provide informed consent.",{"count":495,"type":22},64,[66],"This study (VIHMET) aims to explore how dietary changes, specifically the adoption of a Mediterranean diet, can improve health outcomes in people living with HIV (PLWH) who are on antiretroviral therapy (ART). PLWH often experience chronic inflammation, metabolic disturbances, and elevated cardiovascular risk due to the virus, immune activation, and ART-related side effects. By examining dietary interventions, this study seeks strategies to reduce these risks and enhance quality of life.\n\nThe VIHMET study is a randomized clinical trial involving 64 participants at Hospital del Mar, Barcelona, randomized into control and intervention groups (1:2 ratio). The intervention group will receive personalized nutritional counseling to improve adherence to the Mediterranean diet, focusing on food selection and meal preparation. The control group will follow standard dietary recommendations. Assessments will occur at baseline, week 24, and week 48.\n\nKey health indicators include lipid profiles, markers of inflammation, immune activation, and cardiovascular health, assessed through non-invasive techniques like arterial stiffness and subclinical atherosclerosis measurements. Participants will complete questionnaires on diet adherence, physical activity, and quality of life, alongside anthropometric evaluations.\n\nEligible participants are adults with HIV, undetectable viral loads for 12+ months, and elevated LDL cholesterol with low Mediterranean diet adherence. Exclusion criteria include lipid-lowering drugs, chronic anti-inflammatory therapy, or other active inflammatory\u002Fmetabolic conditions.\n\nThis study aims to improve lipid levels, reduce inflammation, decrease arterial stiffness, and assess diet adherence's impact on quality of life and subclinical atherosclerosis. Results may inform dietary recommendations to reduce cardiovascular risks and enhance holistic care for PLWH.",[499,500,28,501],"HIV Infection","Inflammation","Mediterranean Diet",[503,500,504],"HIV","Coronary Artery","2024-12-31",{"date":479,"type":45},{"date":505,"type":45},{"date":509,"type":22},"2026-07",{"name":511,"class":52},"Parc de Salut Mar",{"id":513,"slug":514,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":330,"enrollmentInfo":519,"targetDuration":4,"studyType":64,"phases":521,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":90},"100507044","the-role-of-plant-based-omega-3-fatty-acids-and-molecular-characterisation-in-individuals-with-cardiovascularcvd-risk-100507044","NCT05882266","The Role of Plant-Based Omega-3 Fatty Acids and Molecular Characterisation in Individuals With Cardiovascular(CVD) Risk","The Role of Plant-Based Omega-3 Fatty Acids and Molecular Characterisation in Individuals With Cardiovascular(CVD) Risk at Beacon Hospital in Selangor","Inclusion Criteria:\n\n* Malaysian aged 18 to 60 years\n* BMI between 18.5 and 39.9 kg\u002Fm2\n* Not on any weight loss therapy\n* Is able to commit to 12 weeks of either intervention\n* Presented signs of metabolic syndrome or moderate hypercholesterolemia\n\nExclusion Criteria:\n\n* Those who are pregnant or lactating\n* Had undergone bariatric surgery\n* Who have acute illnesses such as flu\n* Who has any diabetes-related chronic complications except hypertension and hyperlipidemia\n* Having chronic diseases in particular cancer, liver, kidney, heart disease, stroke, or psychiatric illness\n* Having eating disorder or hypothyroidism",{"count":520,"type":22},72,[66],"The goal of this clinical trial is to investigate the outcome of plant-based omega-3 intervention on lipid profile and blood pressure after 12 weeks and to study the molecular markers associated with the incidence of CVD risk. The main questions it aims to answer are:\n\n* What is the role of plant-based omega-3 intervention on lipid profile and blood pressure of individuals with CVD risk after 12 weeks?\n* What is the association between unique molecular markers and plant-based omega-3 intervention among individuals with CVD risk?\n\nParticipants will be subjected to two groups:\n\n* Treatment group: Receive standard dietary therapy and plant-based omega-3 supplemental beverage consumed once daily during breakfast\n* Control group: Receive only standard dietary therapy\n\nResearcher will compare between treatment and control group to see the effect of plant based omega-3 on lipid profile and blood pressure after 12 weeks",[28],[525,243,526,527,528],"cvd risk","plant omega","plant based omega 3","omega 3","2024-12-11",{"date":531,"type":45},"2024-12-16",{"date":533,"type":22},"2024-12-20",{"date":483,"type":22},{"name":536,"class":52},"Universiti Putra Malaysia",{"id":538,"slug":539,"hasResults":11,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":401},"100570962","cardiometabolic-risk-of-obese-subjects-cross-sectional-study-100570962","NCT06714058","Cardiometabolic Risk of Obese Subjects: Cross-sectional Study","Cardiometabolic Risk of Obese Subjects: Cross-sectional Study for the Identification of Genetic, Laboratory and Clinical Determinants","MiRNome","Inclusion Criteria:\n\n* • Age \\> 18 years\n\n  * BMI \\> 30 Kg\u002Fm2\n  * In primary prevention for cardiovascular disease\n  * Ability to communicate, make themselves understood and adhere to study-specific procedures\n  * Willingness to participate in the study and obtain informed consent\n\nExclusion Criteria:\n\n* Patients already enrolled by the Research Units involved in the enrolment\n* Glycated hemoglobin level \\> 55 mmol\u002FL\n* Patients suffering from obesity secondary to endocrinological diseases or iatrogenic causes\n* Patients with heterozygous Familial Hypercholesterolemia (Dutch Lipid Score - DLS\\>8)\n* Patients suffering from hypercholesterolemia secondary to lipid or iatrogenic extra-metabolic pathologies\n* Patients suffering from systemic inflammatory or oncological diseases\n* Patients on active treatment with GLP-1 analogues\n* Pregnancy and breastfeeding\n* Any medical or surgical condition that makes the patient's adherence to the study protocol complex or inconsistent.",{"count":360,"type":22},"experimental study with analysis on tissues. This study aims to study cardiometabolic risk from a genetic, clinical, instrumental and laboratory point of view in a population of subjects with obesity.",[548,28,549],"Obesity and Obesity-related Medical Conditions","Genetics",{"date":551,"type":45},"2024-12-05",{"date":553,"type":22},"2024-11-30",{"date":555,"type":22},"2025-04-30",{"name":557,"class":52},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":559,"slug":560,"hasResults":11,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":566,"targetDuration":567,"studyType":23,"phases":4,"briefSummary":568,"conditions":569,"keywords":572,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":90},"100541126","glycoxidation-arterial-biomechanics-and-target-organ-damage-100541126","NCT06325800","Glycoxidation, Arterial Biomechanics, and Target Organ Damage","The Role of Glycoxidation on Arterial Biomechanics and Target Organ Damage in Patients With Moderate to High Cardiovascular Risk. The GlycOxiTod Observational Multicentric Registry","GlycOxiTod","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Moderate to high Cardiovascular Risk estimated by SCORE2OP.\n* Signed written consent for participation in the study.\n\nExclusion Criteria:\n\n* Absence of current smoking habit and in the last 6 months.\n* High-risk alcohol consumption (More than 10 and 20 g\u002Fday in women and men, respectively).\n* Presence of Diabetes mellitus.\n* Established cardiovascular disease, including heart failure, ischemic heart disease, valvular heart disease, atrial fibrillation, peripheral artery disease, and cerebrovascular disease.",{"count":232,"type":22},"5 Years","Vascular target organ damage (TOD), defined as structural or functional deleterious changes in large and small arteries, is related to unfavorable arterial biomechanics, atherosclerosis and arteriosclerosis. Endothelial dysfunction due to unfavorable redox and glycation states on the bases of these phenomena. However, little is known about the role of glycoxidation on arterial biomechanics and TOD in apparently healthy individuals. The main hypothesis is that glycation and glycoxidation status are associated with arterial biomechanical abnormalities and TOD in patients with moderate to high cardiovascular risk. This is an observational, ambispective, and multicenter project that will include non-smoking patients over 18 years, without diabetes mellitus or established cardiovascular disease. Demographic, epidemiological, and clinical-anthropometric variables will be collected, including data from ambulatory blood pressure monitoring. The investigators will measure the serum percentage of glycated hemoglobin, glycated albumin, and fructosamine levels; along with quantification of skin advanced glycation and glycoxidation end productos (AGEs). Plasma concentration, activity, and structure of catalase, glutathione peroxidase, and superoxide dismutase in relation to the patient's glycation and glycoxidation status will be also evaluated. Concurrently, several biomechanical parameters will be assessed in the Common, Internal Carotid Artery, and distal limb arteries using ultrasound exploration. Incipient microvasculature damage will be also evaluated by retinal image. Patients will be followed up for the development of arterial biomechanical abnormalities and TOD, along with cardiovascular events.",[570,28,571],"Oxidative Stress","Target Organ Damage",[573,574,575,576,577,578],"glycation","antioxidant","target organ damage","arterial biomechanic","carotid","glycoxidation","2024-04-06",{"date":581,"type":45},"2024-04-09",{"date":583,"type":45},"2024-01-01",{"date":585,"type":22},"2029-12-31",{"name":587,"class":52},"Complejo Hospitalario Universitario de Santiago"]